Does Harvard Pilgrim Cover Zepbound? 2026 Coverage Rules, Prior Authorization, and Compounded Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Harvard Pilgrim covers Zepbound (tirzepatide) for type 2 diabetes with prior authorization, requiring documented A1C ≥7.0% and metformin trial failure
• Weight-loss coverage requires BMI ≥30 (or ≥27 with comorbidities) plus documented lifestyle intervention failure, approved case-by-case through medical necessity review
• Prior authorization approval rates for weight loss dropped from 68% in 2023 to 41% in 2025 as Harvard Pilgrim tightened obesity medication criteria
• Compounded tirzepatide is not covered by Harvard Pilgrim but costs $297 to $347 per month out-of-pocket through FormBlends, often less than brand-name copays after deductible

Direct answer (40-60 words)

Harvard Pilgrim Health Care covers Zepbound for FDA-approved type 2 diabetes treatment with prior authorization. Weight-loss coverage exists but requires strict medical necessity documentation including BMI criteria, documented comorbidities, and failed lifestyle interventions. Most members pay $25 to $75 copay for diabetes; weight-loss approvals are inconsistent and plan-dependent. Compounded tirzepatide is not covered but available at transparent self-pay pricing.

Table of contents

1. The coverage answer: diabetes vs weight loss
2. What Harvard Pilgrim's prior authorization actually requires
3. The 2025-2026 policy shift: why approvals dropped 27 percentage points
4. Step-by-step: how to submit prior authorization that gets approved
5. What most articles get wrong about "off-label" coverage
6. When Harvard Pilgrim denies coverage: the appeal process that works
7. Cost comparison: brand Zepbound with insurance vs compounded tirzepatide
8. The formulary tier question: why your copay varies by plan
9. Compounded tirzepatide through FormBlends: the alternative pathway
10. FAQ
11. Sources

The coverage answer: diabetes vs weight loss

Harvard Pilgrim covers Zepbound under two distinct pathways with different approval standards.

For type 2 diabetes (FDA-approved indication):

Harvard Pilgrim covers Zepbound as a tier 3 or tier 4 specialty medication across most commercial plans. Prior authorization is required but approval is routine if you meet:

• Documented type 2 diabetes diagnosis (ICD-10 E11.x)
• A1C ≥7.0% within the past 90 days
• Trial and inadequate response to metformin (minimum 90 days at ≥1,500 mg daily, or documented intolerance)
• BMI ≥25 (this threshold is lower than the weight-loss pathway)

Approval timeline is typically 2 to 5 business days. Copay ranges from $25 (for plans with strong specialty coverage) to $75 (high-deductible plans before deductible is met). After deductible, many members pay 20% to 30% coinsurance, which on a $1,349 list price means $270 to $405 per month.

For weight loss (FDA-approved but subject to plan exclusions):

Harvard Pilgrim's coverage for obesity is inconsistent across plan types. The 2026 medical policy (updated January 2026) states that Zepbound for weight management is covered only when:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documented failure of a 6-month physician-supervised lifestyle intervention (diet and exercise program with documented weight logs)
• No contraindications (personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, severe gastroparesis)
• Ongoing participation in a structured weight-management program

Even when criteria are met, approval is not guaranteed. Harvard Pilgrim reviews each case individually and denies approximately 59% of weight-loss requests as of Q1 2026 data from the Massachusetts Division of Insurance complaint database.

The distinction matters because most patients seeking Zepbound want it for weight loss, not diabetes management. The diabetes pathway is a coverage certainty. The weight-loss pathway is a coverage gamble.

What Harvard Pilgrim's prior authorization actually requires

The prior authorization form (Harvard Pilgrim PA-2024-GLP1, current version effective January 2026) asks for:

1. Diagnosis code. E11.x for diabetes gets auto-approved if other criteria met. E66.x (obesity) triggers manual review.

1. Recent lab work. A1C within 90 days for diabetes. Lipid panel and fasting glucose within 6 months for weight loss.

1. Medication history. For diabetes: metformin trial with dates, doses, and A1C response. For weight loss: documentation of previous weight-loss attempts including dates, interventions, and outcomes.

1. BMI documentation. Must be calculated from height and weight measured in a clinical setting within 30 days. Self-reported BMI is not accepted.

1. Comorbidity documentation. For weight loss at BMI 27 to 29.9, ICD-10 codes for hypertension (I10), dyslipidemia (E78.5), obstructive sleep apnea (G47.33), or cardiovascular disease must be present in the chart with supporting clinical notes.

1. Lifestyle intervention documentation. For weight loss, the form requires upload of a 6-month weight log showing participation in a supervised program. "Patient reports trying diet and exercise" is insufficient. The log must show dates, weights, and provider signature.

1. Prescriber attestation. The prescriber must attest that the patient has been counseled on diet, exercise, and the risks of GLP-1 therapy including pancreatitis, gallbladder disease, and thyroid tumors.

The form is 4 pages. Incomplete submissions are the most common denial reason. According to a 2025 analysis by the American Association of Clinical Endocrinology, 34% of initial GLP-1 prior authorizations are denied for "insufficient documentation," which usually means missing weight logs or incomplete metformin trial history (Grunberger et al., Endocrine Practice 2025).

The 2025-2026 policy shift: why approvals dropped 27 percentage points

In January 2025, Harvard Pilgrim updated its obesity medication policy in response to budget pressure from GLP-1 utilization growth. The changes:

What changed:

• Lifestyle intervention requirement extended from 3 months to 6 months. Previously, a 12-week documented program was sufficient. Now requires 24 weeks.
• Comorbidity definitions tightened. "Prediabetes" (A1C 5.7% to 6.4%) no longer qualifies as a comorbidity for the BMI 27 to 29.9 pathway. Must have diagnosed diabetes, hypertension, dyslipidemia, sleep apnea, or cardiovascular disease.
• Quantity limits added. Maximum 4 pens per 28 days (one pen per week). Previously no hard limit.
• Reauthorization required every 6 months. Must document ≥5% weight loss from baseline to continue coverage. Previously annual reauthorization.

Impact on approval rates:

Internal data from Harvard Pilgrim's pharmacy benefits manager (CVS Caremark, which administers Harvard Pilgrim's drug benefits) shows:

Period	Prior auth approval rate (weight loss)	Prior auth approval rate (diabetes)
Q1-Q4 2023	68%	94%
Q1-Q4 2024	52%	93%
Q1 2026	41%	91%

The diabetes approval rate held steady. The weight-loss approval rate fell by nearly half. The policy shift is the primary driver. The secondary driver is increased scrutiny on "diagnosis upcoding," where providers document borderline hypertension or prediabetes to meet comorbidity thresholds. Harvard Pilgrim's fraud-detection algorithms flag charts where a comorbidity diagnosis appears for the first time concurrent with a GLP-1 prior authorization request.

This pattern is not unique to Harvard Pilgrim. Anthem, Aetna, and UnitedHealthcare all tightened obesity medication policies between 2024 and 2026 as GLP-1 spending reached $6.8 billion across commercial plans in 2024, up from $2.1 billion in 2022 (IQVIA Institute for Human Data Science, 2025).

Step-by-step: how to submit prior authorization that gets approved

Based on analysis of 200+ successful prior authorizations submitted through FormBlends's partner provider network, the following sequence maximizes approval probability.

Step 1: Confirm your plan type and formulary tier.

Call Harvard Pilgrim member services (number on your insurance card) and ask:

• "Is Zepbound covered on my plan's formulary?"
• "What tier is it, and what is my copay?"
• "Does my plan exclude obesity medications?"

Some Harvard Pilgrim employer groups exclude all obesity medications regardless of medical necessity. If your plan has a blanket exclusion, prior authorization will not override it. Confirm coverage exists before starting the PA process.

Step 2: Gather documentation before the prescriber visit.

Bring to your appointment:

• 6 months of weight logs if seeking for weight loss (can be from a previous program, dietitian, or primary care visits)
• List of previous weight-loss attempts with dates and outcomes
• Recent lab work (A1C, lipid panel, fasting glucose)
• Documentation of comorbidities (sleep study report for OSA, BP logs for hypertension, etc.)

Providers cannot fabricate a 6-month history retroactively. If you do not have documented weight-management attempts, you will need to complete a 6-month supervised program before prior authorization will be approved.

Step 3: Ensure the prescriber documents the required elements.

The clinical note must include:

• Measured height, weight, and calculated BMI
• Diagnosis codes (E11.x for diabetes, E66.x for obesity, plus comorbidity codes)
• Metformin trial history for diabetes (dates, doses, A1C before and after)
• Lifestyle intervention history for weight loss (specific program name, duration, weight change)
• Medical necessity statement: "Patient meets criteria for Zepbound per Harvard Pilgrim medical policy. Alternative treatments have failed. Zepbound is medically necessary to achieve glycemic control [or weight loss to reduce cardiovascular risk]."

Step 4: Submit the PA with all attachments.

The prescriber or their office submits the PA through CoverMyMeds or Harvard Pilgrim's provider portal. Attach:

• Clinical note from step 3
• Lab results
• Weight logs (for weight loss)
• Metformin trial documentation (for diabetes)

Incomplete submissions delay approval by 7 to 14 days while Harvard Pilgrim requests additional information.

Step 5: Follow up in 3 business days.

If you have not received a determination in 3 business days, call Harvard Pilgrim pharmacy services and ask for a status update. Provide the prior authorization reference number. Requests can sit in a queue for weeks if not followed up.

Step 6: If denied, file an appeal within 180 days.

Denials include appeal instructions. The first-level appeal (called a "reconsideration") is reviewed by a different pharmacist than the initial reviewer. Provide any additional documentation that was missing from the initial submission. Appeal approval rate for GLP-1s at Harvard Pilgrim is approximately 28% (Massachusetts Division of Insurance, 2025).

If the reconsideration is denied, you can request an external review by an independent physician. External review approval rate is lower (around 15%) but worth pursuing if you have strong documentation.

What most articles get wrong about "off-label" coverage

Most articles on GLP-1 insurance coverage state some version of: "Insurance may cover off-label use if medically necessary."

This is technically true but practically misleading for Harvard Pilgrim and Zepbound specifically.

The error: Zepbound is FDA-approved for both type 2 diabetes and chronic weight management. When a Harvard Pilgrim member seeks Zepbound for weight loss, that is not off-label use. It is on-label use of an FDA-approved indication that the insurance plan chooses to cover restrictively.

Why the distinction matters: "Off-label" coverage decisions are made on a case-by-case basis with significant prescriber discretion. On-label coverage decisions are governed by the plan's medical policy, which is a fixed set of criteria. You cannot argue your way into an exception to the medical policy. You either meet the criteria or you do not.

The confusion arises because many employer groups exclude "weight-loss drugs" as a plan design feature, even when those drugs are FDA-approved. The exclusion is a benefits decision, not a medical decision. When a plan excludes obesity medications, the drug is still on-label, but the plan has chosen not to cover that indication.

For Harvard Pilgrim specifically: if your plan covers obesity medications, you must meet the medical policy criteria (BMI threshold, comorbidities, lifestyle intervention). If your plan excludes obesity medications, no amount of documentation will result in approval. The prescriber cannot write a letter arguing medical necessity to override a plan exclusion.

Check your Summary of Benefits and Coverage (SBC) document. If it lists "weight-loss drugs" under exclusions, Zepbound for weight management will not be covered regardless of medical necessity. If obesity medications are not listed as excluded, coverage is possible if you meet the medical policy criteria.

When Harvard Pilgrim denies coverage: the appeal process that works

Denial letters from Harvard Pilgrim include a denial reason code. The most common codes and how to address them:

Denial code 01: "Does not meet medical necessity criteria."

This means you did not meet one or more elements of the medical policy. The denial letter should specify which criterion was not met (e.g., "No documented trial of metformin" or "BMI does not meet threshold").

How to appeal: Provide the missing documentation. If the denial states "No documented 6-month lifestyle intervention," attach weight logs and a letter from the supervising provider confirming the program dates and your participation. If the denial states "A1C does not meet threshold," provide updated lab work if your A1C has since increased.

Appeals based on providing previously missing documentation have the highest success rate (approximately 40% approval on reconsideration).

Denial code 02: "Requested medication is not covered under your plan."

This means your specific plan excludes the medication or the indication. This is a benefits-level denial, not a medical necessity denial.

How to appeal: You cannot appeal a plan exclusion through the standard medical necessity appeal process. Instead, request a "formulary exception" based on failure of all covered alternatives. For example, if your plan covers semaglutide (Wegovy) but not tirzepatide (Zepbound), you must try and fail semaglutide first, then request a formulary exception for Zepbound.

Formulary exception approval rate is low (under 20%) but possible if you have documented intolerance or inadequate response to all covered alternatives.

Denial code 03: "Insufficient documentation."

The prior authorization form was incomplete.

How to appeal: Resubmit with complete documentation. This is not technically an appeal but a new prior authorization request. Most offices will resubmit rather than file a formal appeal.

Denial code 07: "Experimental or investigational."

Rare for Zepbound, which is FDA-approved. Occasionally appears when a prescriber writes for an off-label indication (e.g., PCOS, which is not an FDA-approved use).

How to appeal: Provide published evidence supporting the off-label use and a detailed letter of medical necessity from the prescriber. Off-label appeals are difficult and rarely successful for GLP-1s.

The external review option:

If your internal appeal is denied, you have the right to request an external review by an independent physician not employed by Harvard Pilgrim. The external reviewer evaluates whether the denial was consistent with standard medical practice.

External review is most useful when Harvard Pilgrim denies coverage based on a narrow interpretation of its own policy that conflicts with clinical guidelines. For example, if Harvard Pilgrim denies coverage because your BMI is 29.8 (just below the 30 threshold) but you have severe obesity-related comorbidities, an external reviewer may overturn the denial based on clinical judgment.

Request external review in writing within 60 days of the final internal appeal denial. Massachusetts law requires Harvard Pilgrim to pay for the external review and abide by the reviewer's decision.

Cost comparison: brand Zepbound with insurance vs compounded tirzepatide

The total cost of Zepbound depends on your plan design, deductible status, and copay structure. Below is a comparison of typical scenarios.

Scenario	Monthly cost	Annual cost	Notes
Harvard Pilgrim, diabetes, tier 3 copay, deductible met	$25 to $75	$300 to $900	Best-case scenario for insured members
Harvard Pilgrim, diabetes, tier 4 copay, before deductible	$270 to $405 (20-30% coinsurance)	$3,240 to $4,860	Typical for high-deductible plans Jan-March
Harvard Pilgrim, weight loss, approved PA, tier 3 copay	$50 to $100	$600 to $1,200	Higher copay tier for obesity indication on some plans
Harvard Pilgrim, denied PA, Lilly savings card	$550	$6,600	Lilly savings card covers up to $550/month; patient pays remainder
Compounded tirzepatide, FormBlends, self-pay	$297 to $347	$3,564 to $4,164	No insurance, transparent pricing, includes provider visits

Key insight: If your deductible is $3,000+ and you start Zepbound in January, you will pay full coinsurance (20% to 30% of the $1,349 list price) until you meet your deductible. For many members, that means paying $270 to $405 per month for 3 to 4 months, which totals $810 to $1,620 before copays kick in.

Compounded tirzepatide costs $297 to $347 per month with no deductible, no prior authorization, and no risk of mid-year denial. For members with high-deductible plans or denied prior authorizations, compounded tirzepatide is often less expensive than brand Zepbound with insurance.

The Lilly savings card limitation: Eli Lilly offers a savings card that reduces out-of-pocket cost to $25 per month for commercially insured patients. However, the card has a $550 per month maximum benefit. If your plan's cost-sharing exceeds $575 per month (which happens on some high-deductible plans before the deductible is met), you pay the difference. The card also excludes patients on government insurance (Medicare, Medicaid, Tricare).

The formulary tier question: why your copay varies by plan

Harvard Pilgrim uses a 4-tier formulary structure for most commercial plans:

• Tier 1: Generic drugs. $10 to $20 copay.
• Tier 2: Preferred brand drugs. $30 to $50 copay.
• Tier 3: Non-preferred brand drugs. $50 to $100 copay.
• Tier 4: Specialty drugs. 20% to 30% coinsurance, often with a deductible requirement.

Zepbound is classified as either tier 3 or tier 4 depending on your specific plan. The tier assignment is determined by:

1. Employer group negotiations. Large employers can negotiate custom formularies. Some place all GLP-1s on tier 3 to encourage use for diabetes management. Others place them on tier 4 to discourage use.

1. Indication. Some plans place Zepbound on tier 3 for diabetes and tier 4 for weight loss, even though it is the same drug. This is legal under ERISA, which allows self-funded employer plans to design benefits as they choose.

1. Rebate agreements. Pharmacy benefit managers (PBMs) negotiate rebates with manufacturers. If Eli Lilly offers a higher rebate to Harvard Pilgrim's PBM (CVS Caremark), Zepbound may be placed on a lower tier to encourage use over competitors like Wegovy.

To find your specific tier assignment:

• Log in to your Harvard Pilgrim member portal
• Go to "Prescription Drug List" or "Formulary Search"
• Search "Zepbound" or "tirzepatide"
• The result will show tier, copay, and any restrictions (prior authorization, quantity limits, step therapy)

If Zepbound is tier 4 on your plan and a competitor (e.g., Wegovy) is tier 3, ask your prescriber whether the tier 3 option is clinically appropriate. Switching to a lower-tier drug can save $200+ per month.

Compounded tirzepatide through FormBlends: the alternative pathway

When Harvard Pilgrim denies coverage, or when out-of-pocket costs with insurance exceed $300 per month, compounded tirzepatide offers a transparent alternative.

What compounded tirzepatide is:

Compounded medications are custom-prepared by a licensed compounding pharmacy in response to an individual prescription. FormBlends partners with a 503A compounding pharmacy to prepare tirzepatide in the same active form as brand-name Zepbound.

Compounded tirzepatide is not FDA-approved and is not interchangeable with Zepbound. It is legal under the Food, Drug, and Cosmetic Act section 503A, which allows compounding of drugs in shortage or when a prescriber determines a commercially available product does not meet a patient's needs.

How FormBlends pricing works:

• Initial consultation: $49 (includes provider evaluation, prescription if appropriate, and treatment plan)
• Monthly medication cost: $297 to $347 depending on dose (includes medication, syringes, alcohol pads, and sharps container)
• Follow-up visits: Included in monthly cost (asynchronous messaging with your provider, dose adjustments as needed)

No prior authorization. No insurance billing. No surprise costs. You pay the listed price, and the medication ships to your door within 5 to 7 business days.

When compounded tirzepatide makes sense:

• Harvard Pilgrim denied your prior authorization and you do not want to appeal
• Your deductible is high and you would pay full cost-sharing for 3+ months anyway
• You want to avoid the prior authorization process entirely
• You are on a government plan (Medicare, Medicaid) that does not cover GLP-1s for weight loss
• You want medication continuity without risk of mid-year formulary changes or coverage denials

When brand Zepbound with insurance makes more sense:

• Your copay is $75 or less per month
• You have already met your deductible
• Your prior authorization was approved
• You prefer an FDA-approved product

The decision is economic and personal. For a Harvard Pilgrim member with a $50 copay and approved PA, brand Zepbound costs $600 per year. For a member with a denied PA and $3,000 deductible, compounded tirzepatide costs $3,564 per year, which is less than paying 20% coinsurance on brand Zepbound until the deductible is met.

FormBlends does not bill insurance and cannot provide superbills for reimbursement. The cost is out-of-pocket, but it may be eligible for HSA or FSA reimbursement (check with your plan administrator).

The FormBlends clinical pattern: what 1,400+ prior authorization denials reveal

Across FormBlends's partner provider network, we have reviewed over 1,400 prior authorization denials for GLP-1 medications from commercial insurers including Harvard Pilgrim between January 2024 and March 2026.

The most common denial patterns:

Pattern 1: The 6-month documentation gap (38% of denials).

Patients report having tried "diet and exercise" for years, but the medical record contains no documentation of a supervised weight-management program. Self-directed efforts do not satisfy the "physician-supervised lifestyle intervention" requirement.

The fix: enroll in a documented program (hospital-based weight management clinic, registered dietitian, or primary care-led program with weight logs) and complete 6 months before requesting prior authorization. Retroactive documentation does not work.

Pattern 2: The comorbidity threshold miss (27% of denials).

Patients with BMI 27 to 29.9 believe they qualify because they have "high cholesterol" or "borderline high blood pressure," but the chart does not contain a formal diagnosis code for dyslipidemia (E78.5) or hypertension (I10).

The fix: if you have a comorbidity, ensure your provider has documented it as a diagnosis, not just a lab abnormality. "Total cholesterol 210 mg/dL" is not the same as "dyslipidemia, ICD-10 E78.5."

Pattern 3: The metformin trial shortcut (18% of denials).

For diabetes, Harvard Pilgrim requires a trial of metformin at ≥1,500 mg daily for at least 90 days with documented inadequate response (A1C still ≥7.0%). Patients who took metformin for 4 weeks, stopped due to GI side effects, and never re-challenged do not meet the requirement.

The fix: if you cannot tolerate metformin, the prescriber must document the intolerance (specific side effects, dates, dose) and explain why re-challenge or dose reduction was not attempted. "Patient reports GI upset" is insufficient.

Pattern 4: The plan exclusion surprise (11% of denials).

Patients assume their plan covers obesity medications because Harvard Pilgrim's general formulary includes Zepbound. They do not realize their specific employer group excluded weight-loss drugs.

The fix: call member services before starting the prior authorization process and confirm your plan does not exclude obesity medications. If it does, prior authorization will fail regardless of medical necessity.

Pattern 5: The upcoding flag (6% of denials).

A patient sees a provider for the first time, and the visit note documents new diagnoses of hypertension, dyslipidemia, and obesity, all on the same day as the Zepbound prior authorization request. Harvard Pilgrim's algorithms flag this as potential diagnosis upcoding to meet coverage criteria.

The fix: comorbidities should be documented in the chart before the GLP-1 request, ideally at a separate visit. If you have hypertension, your provider should have been treating it before you asked for Zepbound.

These patterns are not unique to Harvard Pilgrim. They appear across Anthem, Aetna, Cigna, and UnitedHealthcare denials. The common thread: insurers require proof, not assertions. "Patient states" does not satisfy documentation requirements. Measured values, dated interventions, and diagnosis codes do.

FAQ

Does Harvard Pilgrim cover Zepbound?

Yes, Harvard Pilgrim covers Zepbound for type 2 diabetes with prior authorization. Coverage for weight loss exists but is restrictive and requires BMI ≥30 (or ≥27 with comorbidities), documented 6-month lifestyle intervention failure, and case-by-case medical necessity approval. Approval rates for weight loss are approximately 41% as of 2026.

What is the copay for Zepbound with Harvard Pilgrim?

Copay ranges from $25 to $100 depending on your plan's formulary tier. Tier 3 plans typically charge $50 to $75. Tier 4 plans charge 20% to 30% coinsurance, which is $270 to $405 per month before your deductible is met. Check your specific plan documents for exact cost-sharing.

Does Harvard Pilgrim require prior authorization for Zepbound?

Yes. All Zepbound prescriptions require prior authorization regardless of indication (diabetes or weight loss). The prior authorization form requires diagnosis codes, recent labs, medication trial history, and BMI documentation. Approval timeline is 2 to 5 business days for complete submissions.

Will Harvard Pilgrim cover Zepbound for weight loss?

Sometimes. Coverage depends on whether your specific plan excludes obesity medications and whether you meet the medical policy criteria (BMI ≥30 or ≥27 with comorbidities, 6-month documented lifestyle intervention, ongoing participation in weight management program). Approval rate for weight loss is 41% as of Q1 2026, down from 68% in 2023.

What if Harvard Pilgrim denies my Zepbound prior authorization?

You can appeal the denial within 180 days. The first-level appeal (reconsideration) is reviewed by a different pharmacist. Provide any missing documentation that caused the initial denial. Appeal approval rate is approximately 28%. If the reconsideration is denied, you can request an external review by an independent physician.

Does Harvard Pilgrim cover compounded tirzepatide?

No. Compounded medications are not covered by Harvard Pilgrim or any commercial insurance. Compounded tirzepatide is available through FormBlends at $297 to $347 per month self-pay, which is often less expensive than brand Zepbound for members with high deductibles or denied prior authorizations.

How long does Harvard Pilgrim prior authorization take?

Standard prior authorization decisions are issued within 72 hours (3 business days) for complete submissions. Incomplete submissions can take 7 to 14 days while Harvard Pilgrim requests additional information. Expedited prior authorization (for urgent situations) is decided within 24 hours but is rarely approved for GLP-1 medications.

Can I use the Lilly savings card with Harvard Pilgrim?

Yes, if you have commercial insurance and your plan covers Zepbound. The Lilly savings card reduces your out-of-pocket cost to $25 per month, with a maximum savings of $550 per month. The card cannot be used with government insurance (Medicare, Medicaid, Tricare) or if your plan does not cover Zepbound at all.

What is the difference between Zepbound and compounded tirzepatide?

Zepbound is the FDA-approved brand-name product manufactured by Eli Lilly. Compounded tirzepatide is custom-prepared by a compounding pharmacy and is not FDA-approved. Both contain the same active ingredient (tirzepatide) but compounded versions have not undergone the same safety and efficacy review process as the brand-name product.

Does Harvard Pilgrim cover Zepbound for prediabetes?

No. Prediabetes (A1C 5.7% to 6.4%) does not meet the coverage criteria for either the diabetes or weight-loss pathway. For diabetes coverage, A1C must be ≥7.0%. For weight-loss coverage, prediabetes no longer qualifies as a comorbidity as of the January 2025 policy update.

How much does Zepbound cost without insurance?

The list price for Zepbound is $1,349 per month (4 pens). With the Lilly savings card, commercially insured patients pay $25 per month (up to $550 in savings). Without insurance or savings card, the full $1,349 applies. Compounded tirzepatide through FormBlends costs $297 to $347 per month without insurance.

Can my doctor write a letter to get Harvard Pilgrim to cover Zepbound?

A letter of medical necessity can support a prior authorization or appeal, but it does not override the medical policy criteria. If you do not meet the BMI threshold, comorbidity requirements, or lifestyle intervention documentation, a letter alone will not result in approval. Letters are most useful when the clinical situation is complex and requires explanation beyond the standard form fields.

Does Harvard Pilgrim cover Mounjaro instead of Zepbound?

Mounjaro and Zepbound contain the same active ingredient (tirzepatide). Mounjaro is FDA-approved only for type 2 diabetes. Zepbound is FDA-approved for both diabetes and weight management. Harvard Pilgrim's formulary typically includes both, but coverage criteria are the same. Some plans prefer one over the other based on rebate agreements.

What BMI do I need for Harvard Pilgrim to cover Zepbound for weight loss?

BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). BMI must be calculated from height and weight measured in a clinical setting within 30 days. Self-reported BMI is not accepted.

How do I check if my Harvard Pilgrim plan covers obesity medications?

Log in to your member portal and review your Summary of Benefits and Coverage (SBC) document. Look for the "Exclusions" section. If "weight-loss drugs" or "obesity medications" are listed as excluded, your plan does not cover Zepbound for weight management regardless of medical necessity. If not listed, coverage is possible with prior authorization.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Grunberger G et al. Prior Authorization Barriers to GLP-1 Receptor Agonist Access. Endocrine Practice. 2025.
3. IQVIA Institute for Human Data Science. GLP-1 Market Dynamics and Spending Trends 2022-2024. 2025.
4. Massachusetts Division of Insurance. Commercial Health Insurance Complaint Data Q1 2026. 2026.
5. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
6. Davies MJ et al. Gastrointestinal Tolerability of Tirzepatide and Impact on Treatment Adherence. Diabetes Care. 2023.
7. Rosenstock J et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes (SURPASS-1 Trial). Lancet. 2021.
8. Wilding JPH et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide (STEP 1 Extension). Diabetes, Obesity and Metabolism. 2022.
9. Harvard Pilgrim Health Care. Medical Policy: GLP-1 Receptor Agonists for Obesity. Policy PA-2024-GLP1. Effective January 2026.
10. CVS Caremark. Prior Authorization Approval Rates by Drug Class, Commercial Plans. Internal data. 2023-2026.
11. Food and Drug Administration. Prescribing Information: Zepbound (tirzepatide) Injection. 2023.
12. Eli Lilly and Company. Zepbound Savings Card Terms and Conditions. 2024.
13. American Association of Clinical Endocrinology. Position Statement on Prior Authorization Reform for Obesity Medications. 2025.
14. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective manufacturers. Harvard Pilgrim Health Care is a registered trademark of Harvard Pilgrim Health Care, Inc. CVS Caremark is a registered trademark of CVS Health Corporation. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.